Triston Casas remains one of the more intriguing buy-low trade targets in baseball, as the former Red Sox first-round pick still offers middle-of-the-order upside thanks to his left-handed power, ...

Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology. By Christina Jewett and ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

WASHINGTON—In an hour-long meeting in January, Food and Drug Administration career staff laid out their objections to a plan to block a new flu shot from vaccine maker Moderna. They argued that ...

The Food and Drug Administration has refused to review Moderna's application for its seasonal flu vaccine, the company announced on Feb. 10, marking the latest setback for the development of ...

Moderna's mRNA-based pandemic flu vaccine – which had federal funding pulled earlier this year amid an increasingly vaccine-sceptic stance by the Trump administration – has been thrown a lifeline by ...

The Food and Drug Administration has refused to review Moderna’s application for an mRNA flu vaccine, the company revealed Tuesday. While the move came as a surprise to the high-profile vaccine maker, ...

Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once touted as a future blockbuster – after it failed the Phase 3 CMVictory trial ...

Behind the household COVID-19 name, Moderna, is facing a $5 billion patent-infringement lawsuit over vaccine technology. Judge Wolson used a “Star Trek” metaphor, saying that even with the US ...

WASHINGTON — The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday. The ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Moderna (MRNA) reports results for the quarter ended December 2025. While this widely-known consensus outlook is ...

Washington — The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday. The ...